Avidity Biosciences, Inc

Avidity Biosciences — Investor Day (August 2021)

60 slides from Avidity Biosciences's investor day presentation, Aug 2, 2021

  1. Slide 1: Virtual Investor & Analyst Event Series – Volume 2: AOC 1001

    Virtual Investor & Analyst Event Series – Volume 2 : AOC 1001 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of

  3. Slide 3: Our Vision

    Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1

  4. Slide 4: Delivering on Our Vision

    Delivering on Our Vision Progressing robust pipeline in muscle AOC 1001 cleared to proceed with Phase 1/2 MARINATM trial; FDA granted orphan drug designation Anticipated clinical trials for both AOC 1044 for DMD and our AOC FSHD program in 2022 Leveraging expertise in clinical and commercial executi

  5. Slide 5: Advancing our Muscle Disease Franchise of AOCs

    PROGRAM / INDICATION TARGET DISCOVERY / LEAD OPTIMIZATION IND ENABLING PHASE 1/2 MUSCLE DISORDERS AOC 1001: Myotonic Dystrophy Type 1 (DM1) DMPK AOC FSHD Program: Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 AOC 1044: Duchenne Muscular Dystrophy (DMD) Exon 44 Dystrophin Next AOC DMD Programs E

  6. Slide 6: Goals for the Day

    Goals for the Day Provide an overview of our clinical plans for AOC 1001, including a brief recap of our preclinical data Offer a broader perspective on the current treatment landscape for DM1 Answer your questions mAb OLIGO

  7. Slide 7: Highlights from Today

    AOC 1001 cleared to proceed with Phase 1/2 MARINA trial First AOC engineered to target skeletal muscle entering the clinic Phase 1/2 trial in adults with DM1 Trial designed to evaluate safety and tolerability in patients and to identify dose for future studies AOC 1001 granted Orphan Drug Designatio

  8. Slide 8: Speakers

    Sarah Boyce, B.S. President & Chief Executive Officer Art Levin, Ph.D. Chiet Scientific Officer 7 AVIDITY im, M.D. FACC. ‘Medical Officer 1 Nicholas E. Johnson, M.D.,M.Sci., FAAN Research, Department of Neurology, "Commonweatth University

  9. Slide 9: Agenda

    Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Jae Kim, M.D. FACC, CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Sarah Boyce, President and CEO (Moderator) Jae Kim, M.D. FACC, CMO Art Levin, Ph.D., CSO Nicholas E. Johnson, M.D., M.Sci., FAAN Sarah Boyce, Pre

  10. Slide 10: AOC 1001 – A Solid Data Package Supporting Phase 1/2 Studies

    AOC 1001 – A Solid Data Package Supporting Phase 1/2 Studies Art Levin, Ph.D., Chief Scientific Officer

  11. Slide 11: We Followed the Data for Each Component of AOC 1001

    AOC COMPONENTS DATA-DRIVEN COMPONENT CHARACTERISTICS OUR ENGINEERING IMPACT Monoclonal antibody Approved mAbs offer: Well-established safety profiles High specificity and affinity Long half-lives Designed through engineering to be effector function null Epitope selection designed for optimal activit

  12. Slide 12: DM1 Well Suited to an siRNA Approach

    DM1, Caused by a Toxic Gain-of-Function mRNA, is Well Suited to an siRNA Approach MECHANISM OF DISEASE (CUG) n DMPK Mutant DMPK mRNA CUG MBNL MBNL MBNL THERAPEUTIC APPROACH Trinucleotide expansion in DMPK mRNA sequesters an RNA splicing protein MBNL (Muscleblind like) in nuclear foci. Sequestration

  13. Slide 13: AOC 1001 siRNA Showed Activity in Nucleus and Cytoplasm

    The AOC 1001 siRNA Showed Activity in the Nucleus and Cytoplasm and Reduced Nuclear Foci in Patient-Derived Muscle Cells DMPK expression % of mock treatment Cytoplasmic fraction Nuclear fraction Whole cell extract Control siDMPK.19 Nuclear and Cytoplasmic DMPK mRNA Levels in DM1 Patient-Derived Musc

  14. Slide 14: siDMPK.19 Produced a 56% Improvement in Splicing

    The AOC 1001 siRNA (siDMPK.19) Produced a 56% Improvement in Splicing in DM1 Myotubes Treatment Signature (100 Splicing Events)

  15. Slide 15: Durable DMPK mRNA Reduction in Monkey Skeletal Muscles

    % DMPK mRNA Expression in Cynomolgus Monkey Time (weeks) Quadriceps Gastrocnemius Durable ~75% Reduction of DMPK mRNA Observed in Monkey Skeletal Muscles After a Single Dose of 2mg/kg of siDMPK.19

  16. Slide 16: Concentration Responsive DMPK mRNA Reduction in Non-human Primates

    AOC 1001 Reduced Muscle DMPK mRNA in Concentration Responsive Manner in Non-human Primates Necropsy was at 7 weeks, following 3 doses at 0, 3, and 6 weeks NHP Study 6 Gastrocnemius biopsies collected 21 or 28 days after single doses ranging from 0.6 to 15 mg/kg siRNA EC50 <0.1 nM Day 21 or 28 Post D

  17. Slide 17: AOC 1001 Toxicology Results Support Entry into the Clinic

    AOC 1001 Toxicology Results Support Entry into the Clinic No dose limiting toxicity observed in monkey at the highest dose tested No observed platelet or renal toxicity No treatment-related histopathologic toxicity observed in monkey No changes observed in safety pharmacology parameters (cardiac, re

  18. Slide 18: >80% DMPK mRNA Reductions in Skeletal Muscle at 13 Weeks

    AOC 1001 Produced >80% Reductions of DMPK mRNA in Skeletal Muscle at 13 Weeks of Treatment in Monkey No adverse effects associated with DMPK mRNA reduction Skeletal Muscle LD = Latissimus Dorsi, VL = Vastus Lateralis Cardiac Muscle DMPK mRNA reductions observed in left ventricle and diaphragm of >75

  19. Slide 19: AOC 1001 Engineered to Optimize Potential Therapeutic Profile

    AOC 1001 Has Been Engineered to Optimize Potential Therapeutic Profile APPROACHING THE CLINIC Cleared to proceed with Phase 1/2 MARINA trial FDA granted Orphan Drug Designation DELIVERING ON DM1 Delivered RNA product candidate to skeletal muscle in vivo Reduced target mRNA in a broad range of muscle

  20. Slide 20: Agenda

    Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Jae Kim, M.D. FACC, CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Sarah Boyce, President and CEO (Moderator) Jae Kim, M.D. FACC, CMO Art Levin, Ph.D., CSO Nicholas E. Johnson, M.D., M.Sci., FAAN Sarah Boyce, Pre

  21. Slide 21: MARINA: A Phase 1/2 Clinical Trial to Evaluate AOC 1001

    MARINATM: A Phase 1/2 Clinical Trial to Evaluate AOC 1001 in Adult Patients with DM1 Jae Kim, M.D. FACC., Chief Medical Officer

  22. Slide 22: Myotonic Dystrophy Type 1: Disease Overview

    0 APPROVED THERAPIES Myotonic Dystrophy Type 1 (DM1): Disease Overview >40,000 PEOPLE WITH DM1 IN THE US DM1 is a complex disease with symptoms that present with high variability from patient to patient Monogenic, autosomal dominant, progressive disease that primarily affects muscle: skeletal, cardi

  23. Slide 23: DM1 is a Progressive Neuromuscular Disease with Multiple Organ Involvement

    DM1 is a Progressive Neuromuscular Disease with Multiple Organ Involvement Hypersomnia, Executive Dysfunction, Emotional, and Social Difficulties Myotonia, Weakness, Wasting, Pain Arrhythmias, Conduction Blocks Respiratory Muscle Weakness, Aspiration, Sleep Apnea Dysphagia, Dyspepsia, Constipation,

  24. Slide 24: Natural History Study END-DM1

    Avidity is Collaborating on a Large Natural History Study (NHS) in DM1 called END-DM1 END-DM1 is a non-interventional NHS that will advance the understanding of disease progression in DM1 patients END-DM1 is designed and run by the Myotonic Dystrophy Clinical Research Network (DMCRN) 700 patients wi

  25. Slide 25: Patient Reported Outcome Measure DM1-NSM

    Partnering with the DM1 Community to Develop Patient Reported Outcome (PRO) Measure Myotonic Dystrophy Type 1 Neuromuscular Severity Measure (DM1-NSM) DM1-NSM specifically designed for use in clinical trials of DM1 treatments Validation in Phase 1/2 MARINA trial Gaining valuable input directly from

  26. Slide 26: MARINA Phase 1/2 Study Title

    MARINATM: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of AOC 1001 Administered Intravenously to Adult DM1 Patients

  27. Slide 27: Trial Objectives

    Trial Objectives Primary Objective Safety and tolerability of single and multiple doses Secondary Objectives Pharmacokinetics Pharmacodynamics (DMPK mRNA knockdown) Spliceopathy Key Exploratory Objectives Measures of clinical activity: Mobility Muscle strength Muscle function Patient-reported outcom

  28. Slide 28: Trial of AOC 1001 in Adults with DM1

    Trial of AOC 1001 in Adults with DM1 Patient Population: N = ~44; Ages 18-65 Dosing: Single and multi-doses administered via an intravenous (IV) infusion; Multidose quarterly with booster after 6 weeks; Biopsies in all cohorts 1mg/kg* Part A Single Dose (N=8) (1 Cohort) Part B Multi-Ascending Dose (

  29. Slide 29: Dosing Regimen

    Dosing Regimen Single IV Dose: AOC 1001 or placebo Part A Dosing Schedule Multiple IV Dose: AOC 1001 or placebo Part B Dosing Schedule Quarterly Dosing Quarterly Dosing Open Label Extension Study Open Label Extension Study 6 Months Booster Multidose cohort treated quarterly with booster after 6 week

  30. Slide 30: Trial Summary

    Evaluating safety and tolerability in adults with DM1 to identify dose for future studies 1 single dose cohort and 3 multi-dose cohorts Patients have the option to roll over into open label extension (OLE) study Key secondary endpoints focused on DMPK knockdown and spliceopathy biomarkers Explorator

  31. Slide 31: Agenda

    Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Jae Kim, M.D. FACC, CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Sarah Boyce, President and CEO (Moderator) Jae Kim, M.D. FACC, CMO Art Levin, Ph.D., CSO Nicholas E. Johnson, M.D., M.Sci., FAAN Sarah Boyce, Pre

  32. Slide 32: Clinical Impact of Myotonic Dystrophy Type 1

    Clinical Impact of Myotonic Dystrophy Type 1 Nicholas E. Johnson, M.D., M.Sci., FAAN Vice Chair for Research, Department of Neurology, Virginia Commonwealth University Dr. Johnson is an associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at

  33. Slide 33: Clinical Impact of Myotonic Dystrophy Type 1

    Clinical Impact of Myotonic Dystrophy type 1 Nicholas Johnson, MD, Msci, FAAN Vice Chair of Research, Associate Professor Director, Muscular Dystrophy Translational Program Departments of Neurology, Human Molecular Genetics Virginia Commonwealth University

  34. Slide 34: Adult Myotonic Dystrophy Type 1

    Adult Myotonic Dystrophy Type-1 Autosomal Dominant Core symptoms include: Distal weakness Myotonia Early onset cataracts Multisystemic condition

  35. Slide 35: Impact on Other Systems

    Impact on other systems Cardiac arrhythmias Increase with age and weakness Progressive heart block, prolonged QRS and PR interval Monitor with screening ECGs Gastrointestinal symptoms Abdominal pain, constipation, diarrhea Dysphagia Endocrine abnormalities Glucose intolerance, thyroid dysfunction, t

  36. Slide 36: Treatment and Prognosis

    Treatment and Prognosis Current treatment focused on symptomatic care of daytime sleepiness and myotonia Care performed in multidisciplinary environment Mean age of death 55 (cardiac or pulmonary causes)

  37. Slide 37: A Very Common Rare Disease: DM1

    A very common rare disease: DM1 Used 50,536 NYS newborn blood spots to screen for DM1 repeat expansion Used triplet primed PCR to screen Confirmed using asuragen amplidex PCR

  38. Slide 38: Sample Classification

    Sample classification Prevalence: 1:2100

  39. Slide 39: Samples Positive for CTG Repeat Expansion Are Unrelated

    Samples positive for CTG repeat expansion are unrelated

  40. Slide 40: Diagnostic Odyssey

    High prevalence highlights difficulty in diagnostic odyssey On average patients wait 7 years for diagnosis (Hilbert, et al., 2013) Patients without family history at highest risk Commonly diagnosed in families with congenital form

  41. Slide 41: Myotonic Dystrophy Type 1 is Slowly Progressive

    Myotonic dystrophy type 1 is slowly progressive Table 1. Clinical Endpoint Assessment from Prior Multicenter Natural History Studies in DM1 (n=113) Assessment Baseline Reliability (ICC) 12 month decline (SD) % change P-value Endpoint Experience in Neuromuscular Drug Trial 30 foot go 5.1 ft/s 0.88 0.

  42. Slide 42: Heterogenous Progression on 30 ft Walk/Run

    Heterogenous progression on 30 ft walk/run; Precision biomarkers could inform therapeutic response Parameter Baseline 12 month change 12 month SD % change P-Value STOP DM 30 Foot Walk / Run 5.9 0.4 0.8 6.2 0.001 DMCRN 30 Foot Walk/Run 5.9 0.4 1.3 5.9 0.03 Courtesy of J. Statland

  43. Slide 43: Heterogeneous Progression in Forced Vital Capacity

    Heterogeneous Progression in Forced Vital Capacity; Precision biomarkers could inform therapeutic response Parameter Baseline SD 12 month change 12 month SD % change P-Value FVC Upright L 3.2 1.0 -0.1 0.3 -2.5 0.06 FVC Upright PP 80.2 22.0 -1.3 9.2 -1.6 0.24 FVC Supine L 2.9 1.0 -0.2 0.3 -5.2 0.0001

  44. Slide 44: RNA Splicing is a Biomarker

    RNA Splicing is a Biomarker of proximate molecular pathology and potential responses to treatment Wagner SA, et al., 2016 Cell model can titrate degree of mis-splicing by MBNL concentration Individual splicing events change with MBNL concentration

  45. Slide 45: Splicing Biomarkers Correlate with Muscle Functional Assessment

    Splicing Biomarkers Correlate with Muscle Functional Assessment Nakamori, et al., 2013 MRC scale: 5=normal strength 4= mild weakness 3= unable to lift against gravity

  46. Slide 46: Gaps Left in Trial Readiness

    Gaps left in trial readiness Better predicting rate of progression by prior performance Optimizing biomarker collection Identifying other predictors of severity Approaching therapeutic trials has provided urgency to these goals

  47. Slide 47: DMCRN Provides Infrastructure

    DMCRN provides infrastructure VCU (Johnson) (coordinating center) University of Rochester, Rochester (Thornton), Data Coordinating Center University of Florida, Gainesville (Subramony) Houston Methodist, Houston (Greene) Kansas University, Kansas City (Statland) NIH (Mankodi) Stanford, Palo Alto (Da

  48. Slide 48: Ongoing Study: END-DM1

    Ongoing study: END-DM1 700 patient, 2 yr study at 16 centers (US/EU) Supported by FDA (NCATs), MDF, Triplet, Dyne, and Avidity Focus on key COAs to refine development (10m, FVC)

  49. Slide 49: Goals of the Current Study

    Goals of the current study Characterize DM1 severity and disease progression over two years in a large cohort (n = 700) Determine basal levels of impairment using standardized measures motor function and muscle strength and a patient-reported outcome (PRO). Test for patient characteristics at baseli

  50. Slide 50: Anticipation in Myotonic Dystrophy

    Anticipation in myotonic dystrophy: Beyond adult onset CTG repeat expansion may occur between generations Results in symptom onset: At birth (Congenital DM) Between ages 1-10 (Childhood DM) Red arrow = index patient

  51. Slide 51: Congenital Myotonic Dystrophy Manifestations

    Congenital myotonic dystrophy manifestations Defined as onset in first month of life with: Hypotonia Respiratory failure Feeding problems Talipes equinovarus Facial weakness Intellectual impairment Autism spectrum disorder/ ADHD Irritable bowel syndrome Weakness and myotonia develop later

  52. Slide 52: Phases of Myotonic Dystrophy in Childhood

    Phases of myotonic dystrophy in childhood Johnson, et al, 2015 N=150 parents

  53. Slide 53: Phases of Myotonic Dystrophy in Childhood

    Phases of myotonic dystrophy in childhood Johnson, et al, 2015 N=150 parents

  54. Slide 54: Summary

    Summary DM1 is a prevalent disease with significant morbidity and mortality The DMCRN natural history studies inform therapeutic trial design including: COAs Biomarkers This support will be provided to the Avidity program

  55. Slide 55: Agenda

    Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Jae Kim, M.D. FACC, CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Sarah Boyce, President and CEO (Moderator) Jae Kim, M.D. FACC, CMO Art Levin, Ph.D., CSO Nicholas E. Johnson, M.D., M.Sci., FAAN Sarah Boyce, Pre

  56. Slide 56: Q&A

    Q&A Participants: Avidity Management Nicholas E. Johnson, M.D., M.Sci., FAAN Moderator: Sarah Boyce, President and CEO

  57. Slide 57: Agenda

    Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Jae Kim, M.D. FACC, CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Sarah Boyce, President and CEO (Moderator) Jae Kim, M.D. FACC, CMO Art Levin, Ph.D., CSO Nicholas E. Johnson, M.D., M.Sci., FAAN Sarah Boyce, Pre

  58. Slide 58: Closing Remarks

    Closing Remarks Sarah Boyce, President & CEO

  59. Slide 59: Goals for the Day

    Goals for the Day Provide an overview of our clinical plans for AOC 1001, including a brief recap of our preclinical data Offer a broader perspective on the current treatment landscape for DM1 Answer your questions mAb OLIGO

  60. Slide 60: Delivering on the RNA Revolution

    Delivering on the RNA Revolution AOC 1001 cleared to proceed with Phase 1/2 MARINA trial AOC FSHD program & AOC 1044 for DMD anticipated to enter the clinic in 2022 Pursuing preclinical proof of concept in additional skeletal muscle and other tissues DELIVERING NEXT Luke Living with DM1

Avidity Biosciences — Investor Day (August 2021) on 6ix